Tag: advanced
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
TOKYO, May 27, 2022 ̵ […]
Machine learning speeds up search for new sustainable materials
TSUKUBA, Japan, May 25, 2 […]
ATAC and Toyota Establish New Initiative to Support the Social Implementation of Innovative Technologies Begin Collaborations with Universities
Toyota City, Japan, Mar 1 […]
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
TOKYO, Mar 7, 2022 – […]
NEC Releases New iPASOLINK VR4 and 25Gbps Capable iPASOLINK EX Advanced Dual to Support Increased Capacity for 5G Networks
TOKYO, Mar 2, 2022 – […]
Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi’s First Dedicated Compact Proton Therapy System
TOKYO, Feb 2, 2022 – […]
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
TOKYO, Jan 20, 2022 ̵ […]
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
TOKYO and KENILWORTH, N.J […]
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
TOKYO and KENILWORTH, N.J […]
Hitachi: Commenced Demonstration Operation of Cloud-based Advanced Energy Management System in Slovenia
TOKYO, Nov 5, 2021 – […]
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
TOKYO and KENILWORTH, N.J […]
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
TOKYO, May 20, 2021 ̵ […]
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
TOKYO, May 7, 2021 – […]
DENSO Develops Advanced Driver Assistance Products for New Lexus LS, Toyota Mirai
KARIYA, JAPAN, Apr 9, 202 […]
